These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18438906)

  • 1. Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment.
    Villela R; Yuen SY; Pope JE; Baron M;
    Arthritis Rheum; 2008 May; 59(5):706-13. PubMed ID: 18438906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
    Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agreement with guidelines from a large database for management of systemic sclerosis: results from the Canadian Scleroderma Research Group.
    Pope J; Harding S; Khimdas S; Bonner A; ; Baron M
    J Rheumatol; 2012 Mar; 39(3):524-31. PubMed ID: 22247347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).
    Kowal-Bielecka O; Landewé R; Avouac J; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
    Ann Rheum Dis; 2009 May; 68(5):620-8. PubMed ID: 19147617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials.
    Yuen SY; Pope JE
    Rheumatology (Oxford); 2008 Sep; 47(9):1367-72. PubMed ID: 18577549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials.
    Avouac J; Wipff J; Kahan A; Allanore Y
    Ann Rheum Dis; 2008 Jun; 67(6):808-14. PubMed ID: 17901091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research.
    Avouac J; Kowal-Bielecka O; Landewe R; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
    Ann Rheum Dis; 2009 May; 68(5):629-34. PubMed ID: 18957486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.
    Tyndall AJ; Bannert B; Vonk M; Airò P; Cozzi F; Carreira PE; Bancel DF; Allanore Y; Müller-Ladner U; Distler O; Iannone F; Pellerito R; Pileckyte M; Miniati I; Ananieva L; Gurman AB; Damjanov N; Mueller A; Valentini G; Riemekasten G; Tikly M; Hummers L; Henriques MJ; Caramaschi P; Scheja A; Rozman B; Ton E; Kumánovics G; Coleiro B; Feierl E; Szucs G; Von Mühlen CA; Riccieri V; Novak S; Chizzolini C; Kotulska A; Denton C; Coelho PC; Kötter I; Simsek I; de la Pena Lefebvre PG; Hachulla E; Seibold JR; Rednic S; Stork J; Morovic-Vergles J; Walker UA
    Ann Rheum Dis; 2010 Oct; 69(10):1809-15. PubMed ID: 20551155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Best practices in scleroderma: an analysis of practice variability in SSc centres within the Canadian Scleroderma Research Group (CSRG).
    Harding S; Khimdas S; Bonner A; Baron M; Pope J;
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S38-43. PubMed ID: 22691207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database.
    Walker UA; Tyndall A; Czirják L; Denton CP; Farge-Bancel D; Kowal-Bielecka O; Müller-Ladner U; Matucci-Cerinic M;
    Ann Rheum Dis; 2009 Jun; 68(6):856-62. PubMed ID: 18625615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic sclerosis - continuing progress in developing clinical measures of response.
    Furst D; Khanna D; Matucci-Cerinic M; Clements P; Steen V; Pope J; Merkel P; Foeldvari I; Seibold J; Pittrow D; Polisson R; Strand V
    J Rheumatol; 2007 May; 34(5):1194-200. PubMed ID: 17477486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis.
    Zulian F; Woo P; Athreya BH; Laxer RM; Medsger TA; Lehman TJ; Cerinic MM; Martini G; Ravelli A; Russo R; Cuttica R; de Oliveira SK; Denton CP; Cozzi F; Foeldvari I; Ruperto N
    Arthritis Rheum; 2007 Mar; 57(2):203-12. PubMed ID: 17330294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival end point reporting in randomized cancer clinical trials: a review of major journals.
    Mathoulin-Pelissier S; Gourgou-Bourgade S; Bonnetain F; Kramar A
    J Clin Oncol; 2008 Aug; 26(22):3721-6. PubMed ID: 18669458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
    Bérezné A; Valeyre D; Ranque B; Guillevin L; Mouthon L
    Ann N Y Acad Sci; 2007 Sep; 1110():271-84. PubMed ID: 17911442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma.
    Garin MC; Highland KB; Silver RM; Strange C
    J Rheumatol; 2009 Feb; 36(2):330-6. PubMed ID: 19208563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cold stimulus fingertip lacticemy test--an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis.
    Fontenelle SM; Kayser C; Pucinelli ML; Andrade LE
    Rheumatology (Oxford); 2008 Jan; 47(1):80-3. PubMed ID: 18077495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis.
    Distler O; Behrens F; Pittrow D; Huscher D; Denton CP; Foeldvari I; Humbert M; Matucci-Cerinic M; Nash P; Opitz CF; Rubin LJ; Seibold JR; Furst DE;
    Arthritis Rheum; 2008 Jun; 59(6):867-75. PubMed ID: 18512721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.
    Koenig M; Joyal F; Fritzler MJ; Roussin A; Abrahamowicz M; Boire G; Goulet JR; Rich E; Grodzicky T; Raymond Y; Senécal JL
    Arthritis Rheum; 2008 Dec; 58(12):3902-12. PubMed ID: 19035499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
    Henness S; Wigley FM
    Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.